Stock Scorecard
Stock Summary for Dr. Reddy`s Laboratories Ltd (RDY) - $74.02 as of 4/26/2024 3:41:54 PM EST
Total Score
20 out of 29
Currently on the following lists
None
Tim's Recommendation
Buy
Growth List Algorithm Criteria for RDY
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for RDY
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for RDY
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for RDY
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Financial Details for RDY
Company Overview |
|
|---|---|
| Ticker | RDY |
| Company Name | Dr. Reddy`s Laboratories Ltd |
| Country | USA |
| Description | Dr. Reddy's Laboratories Limited is a globally integrated pharmaceutical company. The company is headquartered in Hyderabad, India. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 5/22/2024 |
Stock Price History |
|
| Last Day Price | 74.02 |
| Last Day Price Updated | 4/26/2024 3:41:54 PM EST |
| Last Day Volume | 0 |
| Average Daily Volume | 176,284 |
| 52-Week High | 77.72 |
| 52-Week Low | 52.34 |
| Last Price to 52 Week Low | 41.42% |
Valuation Measures |
|
| Trailing PE | 18.86 |
| Industry PE | 79.17 |
| Sector PE | 56.64 |
| 5-Year Average PE | 19.46 |
| Free Cash Flow Ratio | 1.68 |
| Industry Free Cash Flow Ratio | 12.71 |
| Sector Free Cash Flow Ratio | 30.65 |
| Current Ratio Most Recent Quarter | 2.55 |
| Total Cash Per Share | 44.09 |
| Book Value Per Share Most Recent Quarter | 1,608.58 |
| Price to Book Ratio | 3.70 |
| Industry Price to Book Ratio | 5.66 |
| Sector Price to Book Ratio | 22.15 |
| Price to Sales Ratio Twelve Trailing Months | 0.04 |
| Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.17 |
Share Statistics |
|
| Total Shares Outstanding | 166,528,000 |
| Market Capitalization | 12,326,402,560 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | 7/7/2023 |
| Last Dividend Amount | 0.33 |
| Current Dividend Amount | 0.34 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.49 |
| Trailing Annual Dividend Yield | 0.65% |
| Forward Annual Dividend Rate | 0.54 |
| Forward Annual Dividend Yield | 0.73% |
| 5-Year Dividend Payments Count | 3 |
| 3-Year Average Dividend Yield | 0.61% |
| 5-Year Average Dividend Yield | 0.56% |
| 1-Year Dividend Growth Rate Percentage | 44.93% |
| 3-Year Dividend Growth Rate Percentage | 20.95% |
| 5-Year Dividend Growth Rate Percentage | 11.64% |
| All-Time Dividend Growth Rate Percentage | 8.13% |
| Dividend Payout Ratio | 12.97% |
Income Statement |
|
| Quarterly Earnings Growth YOY | 10.30% |
| Annual Earnings Growth | 91.22% |
| Reported EPS 12 Trailing Months | 3.76 |
| Reported EPS Past Year | 172.75 |
| Reported EPS Prior Year | 3.33 |
| Net Income Twelve Trailing Months | 52,206,000,000 |
| Net Income Past Year | 45,067,000,000 |
| Net Income Prior Year | 23,568,000,000 |
| Quarterly Revenue Growth YOY | 6.60% |
| 5-Year Revenue Growth | 11.60% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 7,342,000,000 |
| Total Cash Past Year | 5,779,000,000 |
| Total Cash Prior Year | 14,852,000,000 |
| Net Cash Position Most Recent Quarter | 3,542,000,000 |
| Net Cash Position Past Year | 5,779,000,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 5,746,000,000 |
| Total Debt Most Recent Quarter | 3,800,000,000 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.99 |
| Total Stockholder Equity Past Year | 232,861,000,000 |
| Total Stockholder Equity Prior Year | 190,527,000,000 |
| Total Stockholder Equity Most Recent Quarter | 267,850,000,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.58 |
| MACD Signal | -0.67 |
| 20-Day Bollinger Lower Band | 66.08 |
| 20-Day Bollinger Middle Band | 72.20 |
| 20-Day Bollinger Upper Band | 78.32 |
| Beta | 0.34 |
| RSI | 54.18 |
| 50-Day SMA | 67.49 |
| 200-Day SMA | 60.78 |
System |
|
| Modified | 4/27/2024 10:06:49 AM EST |